Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

BioPharma « Terug naar discussie overzicht

Genmab, de Deense parel

3.464 Posts, Pagina: « 1 2 3 4 5 6 7 ... 170 171 172 173 174 » | Laatste

Omlaag ↓

[verwijderd] 21 januari 2008 18:42

GENMAB REACHES MILESTONES IN OFATUMUMAB COLLABORATION

Copenhagen, Denmark; January 21, 2008 – Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-CD20®) under the terms of its collaboration with GlaxoSmithKline (GSK). The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007. The third milestone payment of DKK 87.2 million was triggered by the first patient receiving treatment in the Phase III rheumatoid arthritis (RA) program, which occurred in 2008.

Genmab achieved the first development milestone payment of DKK 116.3 million under the GSK collaboration in June, triggered by positive efficacy results in the Phase II RA study.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different to the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

“Genmab and GSK have worked hard to expand development with ofatumumab since our collaboration began in December 2006,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “The successful initiation of the ofatumumab RA and DLBCL programs are a testament to the cooperative spirit of our companies.”

www.genmab.com/PressCentre/RecentNews...

biz.yahoo.com/prnews/080121/ukm010.ht...

messages.finance.yahoo.com/Business_%...

[verwijderd] 28 januari 2008 13:12

Genmab buyout rumor:

Rumour of the day

Drug industry chat is that America’s Biogen, which tried but failed to sell itself last year at the prompting of the activist shareholder Carl Icahn, may be pondering a bid for Genmab, a €2 billion Danish biotech group trialling HuMax, a leukaemia treatment. GlaxoSmithKline has the licence for this drug and may have to counterbid to protect its position.

business.timesonline.co.uk/tol/busine...

[verwijderd] 28 januari 2008 21:31

Danish shares close lower; Carlsberg and Genmab higher UPDATE:

Genmab AS was closed 4 pct up at 335 dkr, amid market speculations US-based Biogen might place a bid for the biotech group.

However, a bid from Biogen was seen as rather unlikely as it would require both drug giant GlaxoSmithKline (GSK) and U.S. biotech firm Medarex sell their 10 pct stakes, Jyske Bank said in a note.

According to Danish legislation a majority shareholder must hold more than 90 pct of the shares in a company in order to force minority owners to sell their shares.

Sydbank analyst Rune Majlund Dahl said if someone is to buy Genmab, GSK is a more plausible bidder than Biogen, as the UK-based pharmaceutical group holds the rights to Genmab's drug candidate HuMax-CD20, which could have large sales potential if phase III trial results prove successful on expected release later in the spring

www.forbes.com/markets/feeds/afx/2008...

biz.yahoo.com/rb/080128/biogenidec.ht...

[verwijderd] 29 januari 2008 12:16

Goldman Sachs placing 2.5mln shares in Genmab

LONDON, Jan 29 (Reuters) - Goldman Sachs said on Tuesday it is placing 2.5 million shares in Danish biotech firm Genmab (GEN.CO: Quote, Profile, Research).

"Bookbuilding will commence immediately. The sale price of the shares will be determined after the books have closed," Goldman Sachs said in a note.

The placing represents 5.6 percent of Genmab's shares in issue, according to Reuters data.

Genmab's shares ended 5 percent higher on Monday after Britain's Times newspaper said on Saturday that U.S.-based Biogen Idec (BIIB.O: Quote, Profile, Research) may be considering a bid for the company. (Reporting by Anshuman Daga; Editing by Rory Channing)

www.reuters.com/article/marketsNews/i...

[verwijderd] 29 januari 2008 12:19

Last Trade: 309.00
Trade Time: 5:56AM ET
Change: -29.00 (-8.58%)

aossa 29 januari 2008 13:32

Medarex verkocht Genmab aandelen

www.reuters.com/article/marketsNews/i...

Genmab next biotech M&A target? Analysts doubt it
Tue Jan 29, 2008 6:59am EST
By Ben Hirschler

LONDON (Reuters) - Denmark's Genmab (GEN.CO: Quote, Profile, Research) is a rare success story in European biotech but speculation that it is about to be taken over may be wide of the mark, according to industry analysts.

Shares in the antibody specialist rose 5 percent on Monday after Britain's Times newspaper said Biogen Idec (BIIB.O: Quote, Profile, Research) was considering a bid in a move that could flush out a counter-offer from Genmab's key partner GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research).

On Tuesday, however, the stock was back down 8 percent as Goldman Sachs placed 2.5 million shares with institutional investors on behalf of Medarex Inc (MEDX.O: Quote, Profile, Research).

The decision by Genmab's sister company to sell down its holding leaves Canaccord Adams analyst Karl Keegan more convinced than ever that a sale of the firm -- which has a market value of around $2.75 billion -- is not imminent.

"Genmab doesn't make sense as a take-out candidate, given what we know about the pipeline today and the fact that its antibody engine is licensed from Medarex," he said.

Analysts at ING agreed. They also pointed to the fact Genmab's biggest new drug hope, the experimental cancer and arthritis treatment HuMax-CD20, was a direct competitor to Biogen's Rituxan.

"We find it immensely unlikely that the anti-trust authorities would allow Biogen Idec to have ownership of the only two drugs in this class. Thus we view Biogen Idec as a very unlikely bidder," they said in a note.

ING estimates HuMax-CD20 accounts for 50 percent of Genmab's net present value. But rights to the drug are locked up, since it has been licensed to Glaxo, which clinched a $2 billion deal with the Danish firm for the product in December 2006.

Glaxo could always decide to buy the whole company but it has little need to do so after cherry-picking Genmab's prime asset, analysts believe.

Glaxo probably also has limited interest in other research at Genmab, having bought a firm with rival antibody technology, called Domantis, around the same time it struck the Genmab deal.

Officials at the companies involved declined to comment.

(Editing by Paul Bolding)

[verwijderd] 29 januari 2008 18:48

GENMAB TO PRESENT AT MERRILL LYNCH GLOBAL PHARMACEUTICAL, BIOTECHNOLOGY AND MEDICAL DEVICE CONFERENCE

Copenhagen, Denmark; January 29, 2008 - Genmab A/S (OMX: GEN) announced today Chief Executive Officer Lisa N. Drakeman, Ph.D., will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York City, New York. Dr. Drakeman's presentation is scheduled for February 5, 2008 at 11:00AM local time. A live and archived webcast of the presentation will be available at

www.genmab.com/PressCentre/RecentNews...,BiotechnologyandMedicalDeviceConference/Language/English.aspx

[verwijderd] 1 februari 2008 16:38

GENMAB’S FINANCIAL CALENDAR FOR 2008
Copenhagen, Denmark; January 31, 2008 - Genmab A/S (OMX: GEN) announces its financial calendar for 2008 as follows:

EVENT
DATE

Publication of the Annual Report for 2007
Monday, March 31, 2008

Annual General Meeting 2008
Wednesday, April 23, 2008

Publication of the Interim Report for the first quarter 2008
Wednesday, May 28, 2008

Publication of the Interim Report for the first half 2008
Wednesday, August 27, 2008

Publication of the Interim Report for the first nine months 2008
Wednesday, October 29, 2008

Publication of the financial reports will be after market close on the date of the event.

www.genmab.com/PressCentre/RecentNews...

[verwijderd] 4 februari 2008 22:33

Goldman Sachs raises stake in Genmab to 9.78 pct UPDATE
02.04.08, 3:31 AM ET

www.forbes.com/markets/feeds/afx/2008...

pim f 9 februari 2008 14:06

quote:
ed k. schreef:
Goldman Sachs raises stake in Genmab to 9.78 pct

oh nee, toch niet (foutje):

05.02.2008 15:31
Genmab says Goldman Sachs corrects stake in company to 6.91 pct

COPENHAGEN (Thomson Financial) - Danish biotech company Genmab (News) AS said Goldman Sachs Group Inc (News) has corrected a statement it made on its stake in the group to state that it holds 6.91 pct as of Feb 1.

Yesterday, Genmab announced that Goldman Sachs held 9.78 pct of the company.

'The Goldman Sachs Group, Inc. has subsequently informed us that they had made a miscalculation and under reference to Section 29 of the Danish Securities Trading Act their ownership in Genmab A/S as of February 1, 2008 consists of 3,078,257 shares, which is 6.91% of the total shares in the Company,' Genmab said in a statement.

PerBech.Thomson@contractor.thomson.com

[verwijderd] 20 februari 2008 20:05

GS reiterated its BUY on:

2/14/08 with same price target of DK 558. Says that if Humax-CD20 becomes succesful in all the indications currently being investigated their target becomes DK 732.

messages.finance.yahoo.com/Stocks_%28...

messages.finance.yahoo.com/mb/GNMSF.PK

[verwijderd] 21 februari 2008 17:04

GENMAB AND PDL BIOPHARMA SIGN PURCHASE AGREEMENT FOR ANTIBODY MANUFACTURING FACILITY

Copenhagen, Denmark and Redwood City, Calif., USA, February 21, 2008 - Genmab A/S (OMX: GEN) and PDL BioPharma, Inc. (Nasdaq: PDLI) announced today that they have entered into an agreement under which Genmab would acquire PDL's antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million to be paid in cash. The transaction also includes land, equipment and access to a leased space housing a development lab.

Genmab expects the Minnesota facility, which has a production capacity of 22,000 liters, will be sufficient to provide a sustainable source of both clinical and commercial scale material for its pipeline. The facility features two 1,000 liter and two 10,000 liter bioreactors, which support the simultaneous manufacture of multiple antibody products and will enable Genmab to transition three antibodies from research to manufacturing per year.

"Over the past few years Genmab has been preparing for the market launch of our late stage antibodies and we continue to build a broad pipeline of antibody products, which currently includes 10 products in clinical development. Consequently, the need to secure significant manufacturing capacity has become an increasing priority," stated Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that the new PDL manufacturing facility, with its complete antibody process development platform, represents our best option to secure manufacturing capacity, allowing Genmab to produce antibodies more efficiently and cost effectively while adding key manufacturing expertise to our capabilities we continue to build for a commercial future."

"We are pleased to enter into this agreement with Genmab, which we believe is the optimal transaction to fully realize the value of our biologics manufacturing facility. Importantly, it also represents another step in delivering on our commitment to maximize the value of PDL's assets for our stockholders, following on the recent sale of our commercial assets," said L. Patrick Gage, Ph.D., interim Chief Executive Officer of PDL.

Genmab plans to retain the approximately 170 employees currently working at the manufacturing facility and does not foresee reducing either the PDL BioPharma or Genmab headcount following the acquisition. In connection with this transaction, Genmab would produce clinical material to supply PDL's investigational studies for certain of its pipeline products under a clinical supply agreement.

Genmab's Torben Lund-Hansen, Ph.D. will serve as President of the manufacturing facility. Dr. Lund-Hansen has served as Vice President, Head of Manufacturing at Genmab since 2002. Previously, Dr. Lund-Hansen was responsible for establishing manufacturing facilities for Novo Nordisk.

The transaction has been approved by the boards of directors of both companies and is expected to close by the end of the first quarter of 2008. The transaction is subject to customary closing conditions, including clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and will become effective as soon as these conditions have been satisfied.

Merrill Lynch & Co. is acting as financial advisor and DLA Piper and Briggs and Morgan, P.A. are acting as legal advisors to PDL in connection with the transaction.

Genmab Conference Call

Genmab's senior management will hold a conference call about the news today, February 21, 2008 at:

3:00 PM CET
2:00 PM GMT
9:00 AM EST

The dial in numbers are as follows:
+1 866 214 7077 (in the US)
+1 416 915 9608 (outside the US)

The conference call will be held in English.

A live webcast of the call will be available at www.genmab.com. The webcast will also be archived on Genmab's website.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

About PDL

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. For more information, please visitwww.pdl.com.

www.genmab.com/PressCentre/RecentNews...

[verwijderd] 21 februari 2008 17:10

Genmab to buy PDL's Minnesota antibody plant

COPENHAGEN, Feb 21 (Reuters) - Danish biotech firm Genmab (GEN.CO: Quote, Profile, Research) said on Thursday it would buy PDL's (PDLI.O: Quote, Profile, Research) Minnesota antibody manufacturing plant for $240 million to secure manufacturing capacity and expertise.

Genmab said in a statement the cash transaction includes land, equipment and access to a leased space housing a development laboratory.

By 1405 GMT, Genmab shares were 2.6 percent higher at 302 crowns, outperforming the Copenhagen bourse's top-20 OMX index , which was up 1.6 percent.

The Danish firm -- a rare success story in European biotech -- has been at the centre of takeover speculation for months with Biogen Idec (BIIB.O: Quote, Profile, Research) and Genmab's key partner GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) mentioned as potential bidders.

"Genmab is clearly aiming at becoming a pharmaceutical company. It puts an end to any takeover speculation, and this is a signal it believes in, and wants to be in charge of, marketing its own products," said Sydbank analyst Rune Dahl.

Genmab said the facility was its best option to secure manufacturing capacity, allowing it to produce antibodies more efficiently and cost effectively while adding key manufacturing expertise.

"Genmab expects the Minnesota facility, which has a production capacity of 22,000 litres, will be sufficient to provide a sustainable source of both clinical and commercial scale material for its pipeline," the Danish group said.

"I think Genmab is in the process of transforming itself from a pure biotech firm to really moving more toward being a pharmaceuticals company with products in the market either through partnership deals or their own launches," said Jyske Bank analyst Frank Andersen.

Genmab said it will retain the approximately 170 staff currently working at the plant.

www.reuters.com/article/marketsNews/i...

[verwijderd] 22 februari 2008 20:09

Some thoughts by some people who are experts on biotech/mabs and know what they are talking about:

Genmab (21 feb. 2008)

Genmab has an unique strategic position in an industy which is now realizing that bio-logicals/antibodies (humane) is playing an increasingly important role in the development of medicines for the coming decennium.
Big Pharma has completely ignored this evolution in antibodies in the last 7-8 years and missed out on the most important innovation in the development of medicines.
Genetech has tried to make it work but has not succeeded at it. They in-licensed Rituxan but have not been able to develop a better version of it. Many other pharmas have tried it also with alternative methods but have failed also.

Big Farma is currently in a major R&D crisis, and they will be confronted in the coming 4 years with the biggest hole ever in their pipeline. Next to acquisitions and drastic restructuring (lowering costs) there are no other shortterm solutions. And now all these pharmaceutical companies want to focus on antibodies, oncology and auto-immuun sicknesses (read: Genmab!)

In the last few years is has been proven that:
a. antibodies work very well in combination with chemotherapy;
b. the combination of various antibodies work very well together;
c. the cost of producing antibodies has dropped by 90% vs 7 years ago;
d. oncology is being treated more and more as a chronic disease;
e. antibodies are much safer than “small molecules” thus get approved faster;
f. only humane antibodies can be used for chronic diseases;
g. an example: Avastin, Herceptin, and Rituxan (antibodies from Gentech) have become blockbuster drugs;
h. antibodies are a good adjuvant for vaccins and the vaccin market has grown strongly and has become important;

The collaboration with GSK is extremely valuable but Amgen and Roche are also very important. We have put a summary of the Genmab pipeline on the next page. Please pay attention to what is stil fully owned by Genmab.

A real value which appraises the big number of promising and large projects (currently 22 clinical studies, of which 7 are in phase 3) realistically, will have to come from the industry. This year another 11 clinical studies will be added, of which 6 will be in phase III. GS gives a value of DK 7732 if CD20 is successful in the current indications and maintains a 7,6% interest in Genmab but the current market price of DK 300 reflects only “lack of understanding, not believing, and no insight”.

The current market value is now so low vs what we think it should be (DK 1200) that one has to ask oneself how this may impact negatively (lower bid than is realistic) on a take-over
But it is likely that de enormous strategic value will compensate for this and will justify a very high take-over premium.

Genmab expects to have this year final Phase III data of CD20, EGFr en CD4 (important triggers for a take-over) and will file 3 Biological License Application Approvals with the FDA.

The odds that Genab will get a bid from one of the big pharmas or big biotech firms is increasing day by day. And as long as it doesn’t happen they will continue to add value which will increase the take-over price. Genmab has a very strong financial position and can afford to wait.

messages.finance.yahoo.com/Stocks_%28...

[verwijderd] 25 februari 2008 23:01

Danish shares higher midmorning led by Genmab, Danske Bank
02.25.08, 4:48 AM ET

COPENHAGEN (Thomson Financial) - Shares were higher midmorning following gains on Wall Street and Asian markets led by Genmab AS, which traded higher following a broker upgrade and by Danske Bank AS.

At 10.27 am, the OMXC20 index was up 3.99 points at 435.81 and the OMXCB Benchmark index gained 3.68 points to 414.98.

Genmab AS was up 7.50 dkr at 312.50. According to RB Boersen news agency, ING (nyse: IND - news - people ) raised its rating for the biotech group to 'hold' from 'sell'.

www.forbes.com/markets/feeds/afx/2008...

www.hemscott.com/news/latest-news/ite...

www.snssecurities.nl/scripts/company/...

[verwijderd] 26 februari 2008 19:36

Genmab sees bulging pipeline supported by new manufacturing site
February 26, 2008: 10:40 AM EST

COPENHAGEN, Feb. 26, 2008 (Thomson Financial delivered by Newstex) -- Danish biotech company Genmab AS expects to start 17 new clinical studies in 2008, chief operating officer Claus Moeller said at the group's investor day in Copenhagen today.

The ongoing development work will be supported by the group's recent acquisition of PDL BioPharma's (NASDAQ:PDLI) antibody manufacturing facility in Minnesota, said group head of manufacturing Torben Lund-Hansen.

Genmab will immediately start projects for the antibodies Humax-TAC and Humax-IL8 at the site, and also expects to transfer other projects from existing manufacturing sites with a view to facilitate production and enhance cost effectiveness, he added.

Including the personnel from the manufacturing site, Genmab expects to increase its workforce to 650-700 by the end of the year, COO Moeller said.

Moeller said the group's drug candidate Humax-CD20 is currently involved in three phase III trials, for the cancer forms CLL and NHL, and for rheumatoid arthritis.

Genmab, which tries its antibodies for as many indications as possible, also sees good prospects for the drug candidate in treatment of multiple sclerosis, and expects to carry out a phase II study for treatment of the disease in 2008, said Moeller, and added the antibody might be useful in another 10 indications.

He said he sees good market potential for the Humax-HepC antibody, for which his group projects clinical studies in hepatitis C during the present year, and for Humax-CD38, which is under development for treatment of the cancer form multiple myeloma.

money.cnn.com/news/newsfeeds/articles...

[verwijderd] 27 februari 2008 17:56

PURCHASE AGREEMENT FOR ANTIBODY MANUFACTURING FACILITY RECEIVES ANTITRUST CLEARANCE

Copenhagen, Denmark; February 26, 2008 – Genmab A/S (OMX: GEN) announced today that the purchase agreement entered into between Genmab and PDL BioPharma, Inc. under which Genmab would acquire PDL’s antibody manufacturing facility has received antitrust clearance from the US antitrust authorities under the Hart-Scott-Rodino Act. This transaction was announced February 21, 2008 and is expected to close by the end of the first quarter of 2008. The US antitrust clearance received today satisfies one of the customary closing conditions required to complete this transaction, which will become effective as soon as all of these conditions have been satisfied

www.genmab.com/PressCentre/RecentNews...

[verwijderd] 2 maart 2008 19:16

GENMAB TO ATTEND TWO MARCH INVESTOR CONFERENCE

Copenhagen, Denmark; February 27, 2008 - Genmab A/S (OMX: GEN) announced today its management will attend two investor conferences in March 2008. Chief Operating Officer Claus Møller will attend the Credit Suisse Global Biotechnology One-on-One Conference in London on March 5-6. Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab, will present at the Lehman Brothers 11th Annual Global Healthcare Conference in Miami, Florida, USA on March 18 at 1:30PM EDT. Dr. Drakeman's presentation will be available via live and archived webcast at www.genmab.com

www.genmab.com/PressCentre/RecentNews...

[verwijderd] 3 maart 2008 18:31

GENMAB AND PEPSCAN TO IDENTIFY HUMAN ANTIBODIES AGAINST INTRACTABLE TARGETS

Copenhagen, Denmark and Lelystad, NL; March 3, 2008 - Genmab A/S (OMX: GEN) and Pepscan today announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets. Intractable targets include those that are difficult to address using commonly available technologies but are highly desirable for targeting with monoclonal antibodies. These difficulties can for example be due to the fact that target proteins are buried to a large extent very close to the cell surface or in the cell membrane or due to poor immunogenicity of the protein or desirable epitopes.

In the collaboration, Pepscan will use its proprietary CLIPS™ technology to identify functional mimics of the essential parts of such intractable targets. These mimics will be used by Genmab to create and select unique therapeutic antibodies using its fully human monoclonal antibody technology.

"As part of our efforts to expand Genmab's pipeline, we continually evaluate disease targets which may effectively be addressed with monoclonal antibodies," said Lisa N. Drakeman Ph.D., Chief Executive Officer of Genmab. "This research collaboration with Pepscan will allow us to include in our evaluations a wider variety of disease targets that may not be easily addressed using standard treatments."

Joost van Bree, CEO of Pepscan Therapeutics comments: "monoclonal antibodies against intractable targets are a significant unmet need. The combination of Pepscan CLIPS™ protein mimicry platform with Genmab's ability to generate fully human monoclonals will enable the partners to develop innovative products for poorly served indications."

About Pepscan Therapeutics

Pepscan Therapeutics is a product focused immunotherapy company based in the Netherlands. It has developed a pipeline of therapeutic vaccine and antibody programs of which the most advanced is in Phase II clinical testing. Pepscan's proprietary CLIPS™ technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs.

About CLIPS™ Technology

Chemically Linked Immunogenic Peptides on Scaffolds (CLIPS™) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains that serve as superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).

Further information is available at www.pepscan.com

www.genmab.com/PressCentre/RecentNews...

[verwijderd] 14 maart 2008 10:12

GENMAB AND PDL BIOPHARMA CLOSE SALE OF ANTIBODY MANUFACTURING FACILITY

Copenhagen, Denmark and Redwood City, Calif., USA; March 13, 2008 – Genmab A/S (OMX: GEN) and PDL BioPharma, Inc. (Nasdaq: PDLI) today announced the closing of the previously announced transaction under which Genmab has acquired PDL’s antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million in cash. The transaction was first announced on February 21, 2008

www.genmab.com/PressCentre/RecentNews...

3.464 Posts, Pagina: « 1 2 3 4 5 6 7 ... 170 171 172 173 174 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	882,63	+12,36	+1,42%	26 apr
AMX	914,42	-2,12	-0,23%	26 apr
ASCX	1.198,74	+7,95	+0,67%	26 apr
BEL 20	3.874,87	+16,93	+0,44%	26 apr
Germany40^	18.177,90	+260,62	+1,45%	26 apr
US30^	38.211,61	0,00	0,00%	26 apr
US500^	5.095,29	0,00	0,00%	26 apr
Nasd100^	17.698,09	0,00	0,00%	26 apr
Japan225^	38.345,55	0,00	0,00%	26 apr
WTI	83,64	0,00	0,00%	26 apr
Brent	87,99	0,00	0,00%	26 apr
EUR/USD	1,0694	-0,0036	-0,33%	26 apr
BTC/USD	63.101,97	-877,90	-1,37%	02:59
Gold spot	2.337,95	0,00	0,00%	26 apr